Advertisement
Advertisement

NKTR

NKTR logo

Nektar Therapeutics

71.75
USD
Sponsored
+0.37
+0.52%
Sep 01, 15:59 UTC -4
Closed
exchange

Pre-Market

71.29

-0.46
-0.64%

NKTR Earnings Reports

Positive Surprise Ratio

NKTR beat 34 of 43 last estimates.

79%

Next Report

Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
$10.63M
/
-$2.17
Implied change from Q2 26 (Revenue/ EPS)
+4.88%
/
+76.42%
Implied change from Q3 25 (Revenue/ EPS)
-9.88%
/
+16.04%

Nektar Therapeutics earnings per share and revenue

On Aug 13, 2026, NKTR reported earnings of -1.23 USD per share (EPS) for Q2 26, beating the estimate of -2.02 USD, resulting in a 39.24% surprise. Revenue reached 10.13 million, compared to an expected 10.63 million, with a -4.72% difference. The market reacted with a -3.82% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 8 analysts forecast an EPS of -2.17 USD, with revenue projected to reach 10.63 million USD, implying an increase of 76.42% EPS, and increase of 4.88% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
BioLineRX Ltd
Report Date
Aug 31, 2026 For Q2 26
Estimate
-
Actual
-$0.77
Surprise
-
FAQ
For Q2 2026, Nektar Therapeutics reported EPS of -$1.23, beating estimates by 39.24%, and revenue of $10.13M, -4.72% below expectations.
The stock price moved down -3.82%, changed from $75.92 before the earnings release to $73.02 the day after.
The next earning report is scheduled for Nov 04, 2026.
Based on 8 analysts, Nektar Therapeutics is expected to report EPS of -$2.17 and revenue of $10.63M for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement